cp wire

CP Wire Articles

Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
  • Edasalonexent has orphan drug status in the US and Europe
  • It has been fast-track status in the US

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced on 9/25/18 the... read more

Tue, 09/25/18 - 10:12 am
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
  • Imfinzi is currently approved in the US for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and... read more
Tue, 09/25/18 - 09:51 am
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
  • Alunbrig achieved a 51% increase in progression free survival compared to crizotinib
  • Alunbrig received Breakthrough Therapy Designation from the FDA for the treatment of patients... read more
Tue, 09/25/18 - 09:33 am
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Huge Oral Mucositis Market
  • Oral mucositis is potentially a 1 billion dollar market
  • Additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the... read more
Mon, 09/24/18 - 10:13 am
Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

AstraZeneca on 9/24/18 announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT-2 inhibitor CVOT... read more

Mon, 09/24/18 - 09:36 am

Pages